Abbott (ABT) announced it has received CE Mark in Europe for the Volt PFA System to treat patients battling atrial fibrillation. With the earlier-than-expected CE Mark, Abbott has begun commercial PFA cases in the EU with physicians who have already gained experience with the Volt PFA System within Abbott’s PFA clinical studies. The company will further expand use of Volt in EU markets throughout the second half of the year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott announces FDA approved IDE for Coronary IVL system
- HHS, FDA announce set of actions and initiatives focused on infant formula
- RFK Jr. to meet with infant formula makers, Bloomberg reports
- Insulet expands Omnipod 5 to four more International markets
- Abbott’s Whitfield case re-trial granted, not overturned, says BofA